The Peptides That Target How You Age — Not Just How You Look

Researchers study how peptide compounds interact with pathways involved in aging, metabolism, and tissue responses. Those investigations are scientifically interesting, but a plausible biological mechanism is not proof that a treatment slows aging or extends life in people.

At My Concierge MD in Beverly Hills, Dr. David Nazarian, a board-certified internal medicine physician, discusses preventive care and emerging treatments in the context of a patient’s medical history and goals. Patients considering peptide therapy should understand the difference between established medical uses and investigational longevity claims.

Biological Age Tests Have Important Limits

Chronological age measures time since birth. Research measures sometimes called biological age use patterns in biomarkers to estimate aspects of aging or disease risk. These tools are not interchangeable, and their interpretation depends on the test and the population in which it was studied.

An association between a biomarker and mortality does not prove that changing that biomarker with a treatment reduces mortality. A lower biological-age score after an intervention does not, by itself, show that tissues have been rejuvenated, disease has been prevented, or lifespan has increased.

Mitochondrial Research Is Not a Proven Longevity Protocol

Mitochondria help cells produce energy, and researchers study their role in age-related changes. Compounds such as elamipretide (also called SS-31) and MOTS-c have attracted attention in this area. Evidence must be evaluated for the exact compound, population, and clinical outcome.

Results from aged animals cannot be presented as demonstrated anti-aging benefits in humans. Likewise, any approval or evidence for a specific disease does not establish general longevity benefits. Combining compounds that target different pathways does not automatically make a treatment effective or safe.

Growth Hormone Pathways and Aging

Hormone patterns change with age, but age-related changes, tiredness, or difficulty recovering from exercise do not by themselves diagnose a hormone deficiency. Evaluation should consider other causes and established treatment options.

CJC-1295, ipamorelin, and sermorelin are discussed in relation to growth hormone signaling. Effects on growth hormone or IGF-1 do not establish a benefit for healthy aging, recovery, or lifespan. CJC-1295/ipamorelin combinations should not be described as established longevity treatment on that basis.

FDA identifies limited clinical data and safety concerns for CJC-1295 and other compounded peptide substances. Medical oversight does not remove those uncertainties. Product-specific regulatory status and evidence must be checked before any treatment is considered.

BPC-157 and Tissue-Repair Claims

Much of the research cited for BPC-157 involves laboratory or animal models. These findings cannot establish that it safely treats human tendon injuries, inflammation, or recovery after surgery. Limited human evidence also leaves important questions about dosing, adverse effects, and longer-term outcomes.

FDA notes insufficient safety information for BPC-157’s proposed routes of administration. Its presence in longevity marketing or use by some practices is not evidence that it is an established standard of care. A patient with an injury should first receive an appropriate diagnosis and discussion of established treatments.

Monitoring Does Not Replace Clinical Evidence

Appropriate testing can help evaluate symptoms and monitor certain treatments, but it cannot turn an unproven intervention into a proven one. Treatment assessment should consider meaningful outcomes such as symptoms, function, and adverse effects, alongside the limitations of any laboratory measurements.

Ask what evidence supports the exact treatment for your situation, whether a product is approved for the proposed use, whether compounding is permitted, and what alternatives are available. A research study, advisory discussion, or compounding-policy change is not equivalent to approval.

Begin with Preventive Care and a Medical Consultation

A healthy-aging plan should address appropriate screening, management of established medical conditions, physical activity, nutrition, and sleep. Emerging interventions require a separate discussion of benefits, harms, uncertainties, and regulatory status.

Contact My Concierge MD at 9301 Wilshire Boulevard, Suite 405A, Beverly Hills, or call (310) 299-8959 to discuss your health concerns and treatment options. A consultation does not imply that a particular investigational peptide is available or appropriate for you.

Primary Sources

FDA: Safety concerns with certain compounded substances; FDA: Section 503A bulk drug substances and category updates.

Medically reviewed by David Nazarian, MD on September 28, 2026